Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Connection

Virginia Borges to Prognosis

This is a "connection" page, showing publications Virginia Borges has written about Prognosis.

 
Connection Strength
 
 
 
0.584
 
  1. Shagisultanova E, Gao D, Callihan E, Parris HJ, Risendal B, Hines LM, Slattery ML, Baumgartner K, Schedin P, John EM, Borges VF. Overall survival is the lowest among young women with postpartum breast cancer. Eur J Cancer. 2022 06; 168:119-127.
    View in: PubMed
    Score: 0.107
  2. Borges VF. Options for Endocrine-Refractory, Hormone Receptor-Positive Breast Cancer: Which Target and When? J Clin Oncol. 2021 12 10; 39(35):3890-3896.
    View in: PubMed
    Score: 0.103
  3. Fisher CM, Klein CE, Kondapalli LA, Elias AD, Borges VF. Management of young breast cancer patients with de novo genetic mutations. Oncology (Williston Park). 2014 Oct; 28(10):895-6.
    View in: PubMed
    Score: 0.063
  4. Callihan EB, Gao D, Jindal S, Lyons TR, Manthey E, Edgerton S, Urquhart A, Schedin P, Borges VF. Postpartum diagnosis demonstrates a high risk for metastasis and merits an expanded definition of pregnancy-associated breast cancer. Breast Cancer Res Treat. 2013 Apr; 138(2):549-59.
    View in: PubMed
    Score: 0.057
  5. Diamond JR, Finlayson CA, Thienelt C, Kabos P, Hardesty L, Barbour L, Klein CE, Rabinovitch R, Elias A, Borges VF. Early-stage BRCA2-linked breast cancer diagnosed in the first trimester of pregnancy associated with a hypercoagulable state. Oncology (Williston Park). 2009 Aug; 23(9):784-91.
    View in: PubMed
    Score: 0.044
  6. Lyons TR, Schedin PJ, Borges VF. Pregnancy and breast cancer: when they collide. J Mammary Gland Biol Neoplasia. 2009 Jun; 14(2):87-98.
    View in: PubMed
    Score: 0.043
  7. Jindal S, Pennock ND, Sun D, Horton W, Ozaki MK, Narasimhan J, Bartlett AQ, Weinmann S, Goss PE, Borges VF, Xia Z, Schedin P. Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes. Nat Commun. 2021 11 03; 12(1):6341.
    View in: PubMed
    Score: 0.026
  8. Tarullo SE, Hill RC, Hansen KC, Behbod F, Borges VF, Nelson AC, Lyons TR. Postpartum breast cancer progression is driven by semaphorin 7a-mediated invasion and survival. Oncogene. 2020 03; 39(13):2772-2785.
    View in: PubMed
    Score: 0.023
  9. Poorvu PD, Gelber SI, Rosenberg SM, Ruddy KJ, Tamimi RM, Collins LC, Peppercorn J, Schapira L, Borges VF, Come SE, Warner E, Jakubowski DM, Russell C, Winer EP, Partridge AH. Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer. J Clin Oncol. 2020 03 01; 38(7):725-733.
    View in: PubMed
    Score: 0.023
  10. Murthy R, Borges VF, Conlin A, Chaves J, Chamberlain M, Gray T, Vo A, Hamilton E. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018 07; 19(7):880-888.
    View in: PubMed
    Score: 0.020
  11. Brown RJ, Sams S, Wolverton DE, Chong T, Borges VF, Rabinovitch RA, Murphy CD. Don't Be Fooled by DCIS. Oncology (Williston Park). 2017 07 15; 31(7):549-51, 560-1.
    View in: PubMed
    Score: 0.019
  12. Jasem J, Fisher CM, Amini A, Shagisultanova E, Rabinovitch R, Borges VF, Elias A, Kabos P. The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided? J Natl Compr Canc Netw. 2017 04; 15(4):494-503.
    View in: PubMed
    Score: 0.019
  13. Ruddy KJ, DeSantis SD, Barry W, Guo H, Block CC, Borges V, Winer EP, Partridge AH. Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen. Clin Breast Cancer. 2014 Dec; 14(6):413-6.
    View in: PubMed
    Score: 0.015
  14. Nunes RA, Li X, Kang SP, Burstein H, Roberts L, Carney W, Blackwell K, Ryan P, Borges V, Iglehart JD, Friedman P, Harris LN. Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy. Int J Biol Markers. 2009 Jan-Mar; 24(1):1-10.
    View in: PubMed
    Score: 0.011
  15. Bowles DW, Rabinovitch R, Borges V, Urquhart A, Singh M, Finlayson C, Elias A. A young woman with a small ER-positive breast cancer, a micrometastatic axillary lymph node, and an intermediate oncotype DX recurrence score. Oncology (Williston Park). 2007 Sep; 21(10):1212-7.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)